Simultaneous Determination of Asperosaponin Ⅵ and Tanshinone ⅡA in Yigong Granules by HPLC

Expand
  • 1.Guiyang Food and Drug Control and Testing Center, Guizhou Guiyang 550081, China;
     2.Guizhou Medical Products Administration Inspection Center, Guizhou Guiyang 550081, China

Received date: 2025-07-17

  Revised date: 2025-10-24

  Accepted date: 2026-01-07

  Online published: 2026-01-07

Abstract

Objective: To establish a high-performance liquid chromatography (HPLC) method for the simultaneous determination of asperosaponin Ⅵ and tanshinone ⅡA in Yigong Granules, in order to improve the quality control standard of this preparation. Methods: HPLC analysis was performed using an Agilent Eclipse Plus C18 column (4.6 mm×250 mm, 5 μm). The mobile phase consisted of 0.1% (v/v) phosphoric acid solution (A) and acetonitrile (B), with gradient elution according to a specified program. The flow rate was set at 1.0 mL·min-1, and the column temperature was maintained at 30 ℃. Detection wavelengths were set at 210 nm for asperosaponin Ⅵ and 270 nm for tanshinone ⅡA, based on their ultraviolet absorption characteristics. The injection volume was 10 μL. Results: Asperosaponin Ⅵ showed a good linear relationship within the concentration range of 23.575 0-707.250 0 μg·mL-1, with a correlation coefficient (r2) of 1.000 0. The average recovery rate was 96.4%, and the relative standard deviation (RSD) was 1.8% (n=6). Tanshinone ⅡA also exhibited a good linear relationship within the concentration range of 1.483 5-44.505 0 μg·mL-1, with an r2 of 1.000 0. The average recovery rate was 94.8%, and the RSD was 1.5% (n=6). Conclusion: A simple, accurate, reproducible, and stable HPLC method was successfully developed for the simultaneous and rapid determination of asperosaponin Ⅵ and tanshinone ⅡA in Yigong Granules. This method is reliable and practical, making it suitable for multi-component quality evaluation of the preparation.

Cite this article

HE Jianping, HUANG Minjie, ZHANG Dan . Simultaneous Determination of Asperosaponin Ⅵ and Tanshinone ⅡA in Yigong Granules by HPLC[J]. CHINESE JOURNAL OF DRUG EVALUATION, 2025 , 42(6) : 431 -431-435 . DOI: magtech-2025-07-17-00001

References

  [1] 杨倩,魏嘉茵,潘婕,等. 益宫颗粒治疗产后恶露不绝的临床综合评价[J]. 药物评价研究,2025,48(1):167-179.
     [2] 张雪姣,杨哲,薛青,等. 中药热奄包穴位热敷结合益宫颗粒促进子宫复旧的临床效果研究[J]. 河北中医药学报,2022,37(6):37-41.
     [3] 刘茂永,黄露,龚乾涛,等. 益宫颗粒联合缩宫素治疗剖宫产术后子宫复旧不全临床效果及对泌乳的影响[J]. 中华中医药学刊,2020,38(7):81-83.
     [4] 许莉,秦玉璇,云凤,等. 黄体酮联合益宫颗粒对药物流产术后阴道出血的临床研究[J]. 中国临床药理学杂志,2021,37(20):2749-2751,2762.
     [5] 王海会,万瑞,郑稳,等. 益宫颗粒联合卡前列素氨丁三醇治疗产后出血的临床研究[J]. 现代药物与临床,2021,36(1):157-160.
     [6] 史淑慧. 益宫颗粒联合缩宫素注射液在初产妇剖宫产分娩产后宫腔积血中的应用[J]. 中国合理用药探索,2019,16 (10):170-172.
     [7] 原国家食品药品监督管理局标准YBZ00312008[S]. 2008.
     [8] 国家药典委员会. 中华人民共和国药典(一部)[S]. 2020年版. 北京:中国医药科技出版社,2020:343-344.
     [9] 田梅,朱泽宇,侯飞侠,等. 基于质谱成像技术分析续断中主要代谢物的组织分布[J]. 亚太传统医药,2025,21(7):57-58.
     [10] 管超,商庆新,等. 续断及其提取物治疗骨关节炎作用机制研究进展[J]. 江苏中医药,2025,57 (3):83-86.
     [11] 李蕴喆,牛泽蕃,王紫瑈,等. 川续断皂苷Ⅵ促进低氧环境下MC3T3-E1 细胞的成骨分化[J]. 中国组织工程研究,2025,29(35):7481-7489.
     [12] 牛民主,殷丽霞,段婷,等. 川续断皂苷Ⅵ通过抑制 PI3K/AKT/NF-κB 通路拮抗肠上皮细胞凋亡缓解TNBS诱导的小鼠克罗恩病样结肠炎[J]. 南方医科大学学报,2024,44 (12):2335-2346.
     [13] 柴争妍,彭新,杨琦帆,等. 丹参及其药对药理作用及临床应用研究进展[J]. 安徽中医药大学学报,2024,43(6):108-112.
     [14] 李自波,郑亚秋,等. 丹参及其有效成分调控血管内皮细胞功能的药理作用机制研究进展[J]. 中草药. 2025,56(14):5324-5332.
     [15] 顾庆香,刘维,丁久力,等. 丹参酮ⅡA治疗类风湿关节炎的作用机制[J]. 中医学报,2024,39(11):2381-2385.
     [16] 宁剑,何春玲,黄健军,等. 丹参酮ⅡA体内外抗炎作用研究[J]. 现代药物与临床, 2019,34(2):292-298.
     [17] 田丹,王东孝,景贤,等. HPLC多指标成分测定结合多元统计分析的益宫颗粒质量控制研究[J]. 现代药物与临床,2023,38(3):559-565.
     [18] 高松红,单柏宇,徐阳,等. HPLC法测定益宫颗粒中阿魏酸的含量[J]. 中国医药指南, 2018,16 (22):10-12.
     [19] 施桂萍,王佳恩,马莉,等. 药材品质与药用植物表型性状间相关性研究进展[J]. 中药材,2024,47(7):1853-1861.
     [20] 郭信东,李明主,李静,等. 续断盐炙前后13种指标性成分的变化研究[J]. 时珍国医国药,2024,35(11):2604-2609.
     [21] 江维克,艾强,周涛,等. 贵州续断药材川续断皂苷Ⅵ含量的地理分布趋势分析[J]. 贵州农业科学,2013,41(8):19-22.
     [22] 仉劲,刘凯凯,柳文,等. 不同移栽时期对丹参产量及有效成分的影响[J]. 中国野生植物资源. 2025,44(3):32-36,42.
     [23] 高宇明,谢艳,张亚琴,等. 不同产地丹参质量评价及指纹图谱研究[J]. 亚太传统医药,2020,16(9):77-81.
Outlines

/

[an error occurred while processing this directive]